Management of patients with homozygous familial hypercholesterolemia.
PEZ@aol.com.
Paul E
PE
Ziajka
D001562:Benzimidazoles / Q000627:therapeutic use; D003131:Combined Modality Therapy; D018752:Diet, Fat-Restricted; D017277:Drug Approval; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000175:diagnosis* / Q000628:therapy*; D008077:Lipoproteins, LDL / Q000378:metabolism*; D008297:Male; D009841:Oligonucleotides / Q000627:therapeutic use; D010956:Plasmapheresis / Q000379:methods*; D011379:Prognosis; D035583:Rare Diseases; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome
C473731:BMS201038; D001562:Benzimidazoles; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008077:Lipoproteins, LDL; D009841:Oligonucleotides; C524142:mipomersen